^
Association details:
| Biomarker: | EGFR V843I + KRAS G13D + AKT1 E17K + PD-L1 overexpression |
|---|---|
| Cancer: | Lung Adenocarcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Long response to Immune Checkpoint Inhibitors in metastatic NSCLC despite EGFR germline mutation. A Case Report
Published date:
09/10/2022
Excerpt:
...we describe the case of a long response to ICIs treatment in a complex metastatic NSCLC with co-occuring EGFR germline and KRAS somatic mutations, high PD-L1 score and a smoking history....Our patient is a 61-year-old woman with a smoking history and a poorly differentiated NSCLC...new generation sequencing (NGS) panel analysis identified activating G13D KRAS, E17K AKT1 mutations with 11% of allelic frequency (AF) both and V843I EGFR mutation at 49% of AF....the patient received front-line pembrolizumab immunotherapy as the PD-L1 was expressed by 50% of cancer cells, with sustained partial response on all tumor sites...
DOI:
https://doi.org/10.1016/j.lungcan.2022.09.005
